Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study

Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study

Peptide receptor radionuclide therapy (PRRT) with radiolabeled SSTR2 agonists is a treatment option that is highly effective in controlling metastatic and progressive neuroendocrine tumors (NETs). Previous studies have shown that an SSTR2 agonist combined with albumin binding moiety Evans blue (deno...

Full description

Saved in:
Bibliographic Details
Main Authors: Wei Guo, Xuejun Wen, Yuhang Chen, Tianzhi Zhao, Jia Liu, Yucen Tao, Hao Fu, Hongjian Wang, Weizhi Xu, Yizhen Pang, Liang Zhao, Jingxiong Huang, Pengfei Xu, Zhide Guo, Weibing Miao, Jingjing Zhang, Xiaoyuan Chen, Haojun Chen
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Radiolabeled somatostatin analog
Neuroendocrine tumor
Evans blue
177Lu-LNC1010
Peptide receptor radionuclide therapy
First-in-human dose escalation study
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383524002004
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2211383524002004

Similar Items